Oxidative phosphorylation as a potential therapeutic target for cancer therapy.
Warburg phenomenon
bioenergetics
immunotherapy
metabolism
mitochondrial respiration
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 01 2020
01 01 2020
Historique:
received:
04
07
2019
revised:
01
08
2019
accepted:
05
08
2019
pubmed:
10
8
2019
medline:
15
2
2020
entrez:
10
8
2019
Statut:
ppublish
Résumé
In contrast to prior belief, cancer cells require oxidative phosphorylation (OXPHOS) to strive, and exacerbated OXPHOS dependency frequently characterizes cancer stem cells, as well as primary or acquired resistance against chemotherapy or tyrosine kinase inhibitors. A growing arsenal of therapeutic agents is being designed to suppress the transfer of mitochondria from stromal to malignant cells, to interfere with mitochondrial biogenesis, to directly inhibit respiratory chain complexes, or to disrupt mitochondrial function in other ways. For the experimental treatment of cancers, OXPHOS inhibitors can be advantageously combined with tyrosine kinase inhibitors, as well as with other strategies to inhibit glycolysis, thereby causing a lethal energy crisis. Unfortunately, most of the preclinical data arguing in favor of OXPHOS inhibition have been obtained in xenograft models, in which human cancer cells are implanted in immunodeficient mice. Future studies on OXPHOS inhibitors should elaborate optimal treatment schedules and combination regimens that stimulate-or at least are compatible with-anticancer immune responses for long-term tumor control.
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Protein-Tyrosine Kinases
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
10-17Informations de copyright
© 2019 UICC.
Références
Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008;13:472-82.
Galluzzi L, Kepp O, Vander Heiden MG, et al. Metabolic targets for cancer therapy. Nat Rev Drug Discov 2013;12:829-46.
Vazquez A, Kamphorst JJ, Markert EK, et al. Cancer metabolism at a glance. J Cell Sci 2016;129:3367-73.
Luengo A, Gui DY, Vander Heiden MG. Targeting metabolism for cancer therapy. Cell Chem Biol 2017;24:1161-80.
Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 2011;10:671-84.
Porporato PE, Filigheddu N, Pedro JMB, et al. Mitochondrial metabolism and cancer. Cell Res 2018;28:265-80.
Wallace DC. Mitochondrial DNA variation in human radiation and disease. Cell 2015;163:33-8.
Tan AS, Baty JW, Dong LF, et al. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. Cell Metab 2015;21:81-94.
Bajzikova M, Kovarova J, Coelho AR, et al. Reactivation of dihydroorotate dehydrogenase-driven pyrimidine biosynthesis restores tumor growth of respiration-deficient cancer cells. Cell Metab 2019;29:399-416.e10.
Goswami CP, Nakshatri H. PROGgeneV2: enhancements on the existing database. BMC Cancer 2014;14:970.
Sancho P, Barneda D, Heeschen C. Hallmarks of cancer stem cell metabolism. Br J Cancer 2016;114:1305-12.
Kuntz EM, Baquero P, Michie AM, et al. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nat Med 2017;23:1234-40.
Lee KM, Giltnane JM, Balko JM, et al. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metab 2017;26:633-647.e7.
Lissanu Deribe Y, Sun Y, Terranova C, et al. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nat Med 2018;24:1047-57.
Rao S, Mondragon L, Pranjic B, et al. AIF-regulated oxidative phosphorylation supports lung cancer development. Cell Res 2019;29:579-91.
Hangen E, Feraud O, Lachkar S, et al. Interaction between AIF and CHCHD4 regulates respiratory chain biogenesis. Mol Cell 2015;58:1001-14.
Vazquez F, Lim JH, Chim H, et al. PGC1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 2013;23:287-301.
Farge T, Saland E, de Toni F, et al. Chemotherapy-resistant human acute myeloid Leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov 2017;7:716-35.
Bosc C, Selak MA, Sarry JE. Resistance is futile: targeting mitochondrial energetics and metabolism to overcome drug resistance in cancer treatment. Cell Metab 2017;26:705-7.
Fischer GM, Jalali A, Kircher DA, et al. Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases. Cancer Discov 2019;9:628-45.
Hayakawa K, Esposito E, Wang X, et al. Transfer of mitochondria from astrocytes to neurons after stroke. Nature 2016;535:551-5.
Zhang L, Zhang J, Ye Z, et al. Pharmacology of ME-344, a novel cytotoxic isoflavone. Adv Cancer Res 2019;142:187-207.
Marlein CR, Zaitseva L, Piddock RE, et al. NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts. Blood 2017;130:1649-60.
Marlein CR, Piddock RE, Mistry JJ, et al. CD38-driven mitochondrial trafficking promotes bioenergetic plasticity in multiple myeloma. Cancer Res 2019;79:2285-97.
Scatena C, Roncella M, Di Paolo A, et al. Doxycycline, an inhibitor of mitochondrial biogenesis, effectively reduces cancer stem cells (CSCs) in early breast cancer patients: a clinical pilot study. Front Oncol 2018;8:452.
Skoda J, Borankova K, Jansson PJ, et al. Pharmacological targeting of mitochondria in cancer stem cells: An ancient organelle at the crossroad of novel anti-cancer therapies. Pharmacol Res 2019;139:298-313.
Zamzami N, Metivier D, Kroemer G. Quantitation of mitochondrial transmembrane potential in cells and in isolated mitochondria. Methods Enzymol 2000;322:208-13.
James AM, Blaikie FH, Smith RA, et al. Specific targeting of a DNA-alkylating reagent to mitochondria. Synthesis and characterization of [4-((11aS)-7-methoxy-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-o n-8-oxy)butyl]-triphenylphosphonium iodide. Eur J Biochem 2003;270:2827-36.
Reily C, Mitchell T, Chacko BK, et al. Mitochondrially targeted compounds and their impact on cellular bioenergetics. Redox Biol 2013;1:86-93.
Boyle KA, Van Wickle J, Hill RB, et al. Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation. J Biol Chem 2018;293:14891-904.
Rohlenova K, Sachaphibulkij K, Stursa J, et al. Selective disruption of respiratory supercomplexes as a new strategy to suppress Her2(high) breast cancer. Antioxid Redox Signal 2017;26:84-103.
Hubackova S, Magalhaes Novais S, Davidova E, et al. Mitochondria-driven elimination of cancer and senescent cells. Biol Chem 2019;400:141-8.
Hubackova S, Davidova E, Rohlenova K, et al. Selective elimination of senescent cells by mitochondrial targeting is regulated by ANT2. Cell Death Differ 2019;26:276-90.
Marzo I, Brenner C, Zamzami N, et al. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 1998;281:2027-31.
Haouzi D, Cohen I, Vieira HL, et al. Mitochondrial permeability transition as a novel principle of hepatorenal toxicity in vivo. Apoptosis 2002;7:395-405.
Le Bras M, Borgne-Sanchez A, Touat Z, et al. Chemosensitization by knockdown of adenine nucleotide translocase-2. Cancer Res 2006;66:9143-52.
Izzo V, Bravo-San Pedro JM, Sica V, et al. Mitochondrial permeability transition: new findings and persisting uncertainties. Trends Cell Biol 2016;26:655-67.
Shi Y, Lim SK, Liang Q, et al. Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma. Nature 2019;567:341-6.
Madeo F, Carmona-Gutierrez D, Hofer SJ, et al. Caloric restriction Mimetics against age-associated disease: targets, mechanisms, and therapeutic potential. Cell Metab 2019;29:592-610.
Ashton TM, McKenna WG, Kunz-Schughart LA, et al. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res 2018;24:2482-90.
Zhang X, Fryknas M, Hernlund E, et al. Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nat Commun 2014;5:3295.
Ellinghaus P, Heisler I, Unterschemmann K, et al. BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I. Cancer Med 2013;2:611-24.
Molina JR, Sun Y, Protopopova M, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med 2018;24:1036-46.
Diamond JR, Goff B, Forster MD, et al. Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers. Invest New Drugs 2017;35:627-33.
Jacque N, Ronchetti AM, Larrue C, et al. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood 2015;126:1346-56.
Lucantoni F, Dussmann H, Llorente-Folch I, et al. BCL2 and BCL(X)L selective inhibitors decrease mitochondrial ATP production in breast cancer cells and are synthetically lethal when combined with 2-deoxy-D-glucose. Oncotarget 2018;9:26046-63.
Pollyea DA, Stevens BM, Jones CL, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med 2018;24:1859-66.
Haq R, Shoag J, Andreu-Perez P, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell 2013;23:302-15.
Vitiello GA, Medina BD, Zeng S, et al. Mitochondrial inhibition augments the efficacy of imatinib by resetting the metabolic phenotype of gastrointestinal stromal tumor. Clin Cancer Res 2018;24:972-84.
Zhang L, Yao Y, Zhang S, et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med 2019;11:eaau1167.
Hitosugi T, Kang S, Vander Heiden MG, et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal 2009;2:ra73.
Ward PS, Thompson CB. Signaling in control of cell growth and metabolism. Cold Spring Harb Perspect Biol 2012;4:a006783.
Liu P, Zhao L, Pol J, et al. Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nat Commun 2019;10:1486.
DeWaal D, Nogueira V, Terry AR, et al. Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. Nat Commun 2018;9:446.
Sun Y, Bandi M, Lofton T, et al. Functional genomics reveals synthetic lethality between phosphogluconate dehydrogenase and oxidative phosphorylation. Cell Rep 2019;26:469-82 e5.
Sica V, Bravo-San Pedro JM, Izzo V, et al. Lethal poisoning of cancer cells by respiratory chain inhibition plus dimethyl alpha-ketoglutarate. Cell Rep 2019;27:820-34 e9.
Zitvogel L, Galluzzi L, Smyth MJ, et al. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013;39:74-88.
Zitvogel L, Rusakiewicz S, Routy B, et al. Immunological off-target effects of imatinib. Nat Rev Clin Oncol 2016;13:431-46.
Zitvogel L, Pitt JM, Daillere R, et al. Mouse models in oncoimmunology. Nat Rev Cancer 2016;16:759-73.
Eikawa S, Nishida M, Mizukami S, et al. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A 2015;112:1809-14.
Cha JH, Yang WH, Xia W, et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol Cell 2018;71:606-20 e7.
Li L, Wang L, Li J, et al. Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer. Cancer Res 2018;78:1779-91.
Perrot I, Michaud HA, Giraudon-Paoli M, et al. Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep 2019;27:2411-25 e9.
Bantug GR, Galluzzi L, Kroemer G, et al. The spectrum of T cell metabolism in health and disease. Nat Rev Immunol 2018;18:19-34.
Weinberg SE, Singer BD, Steinert EM, et al. Mitochondrial complex III is essential for suppressive function of regulatory T cells. Nature 2019;565:495-9.